Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EYU688 · 1 trial · 1 indication
Efficacy assessment of EYU688. It will allow to quantify the viremia reduction at 48 hours post treatment start from baseline.
| Arm | Type | Description |
|---|---|---|
| EYU688 | EXPERIMENTAL | EYU688 administered by oral route |
| Placebo | PLACEBO_COMPARATOR | Matching placebo |
| Name | Type | Description |
|---|---|---|
| EYU688 | DRUG | EYU688 administered by oral route |
| Placebo | DRUG | Matching placebo administered orally as capsules |
Inclusion Criteria: * Male or female, 18 - 60 years old (inclusive). * History or presence of fever (≥ 38°C). At least one of the following criteria indicating dengue infection: * Nausea or vomiting. * Presence of rash, aches or pains including headache, muscle or joint pain. * Onset of fever ≤ 48 ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 5 | PHASE3 | Tetravalent Dengue Vaccine |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | EYU688 |
| Sanofi SA Sponsored ADR | SNY | 1 | - | Undisclosed |
| Abbott Laboratories | ABT | 1 | - | Undisclosed |
| Danaher Corporation | DHR | 1 | - | Undisclosed |
EYU688 is an investigational small molecule being developed for the treatment of dengue fever. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities. The drug is being studied in patients with dengue to assess its efficacy, safety, and pharmacokinetics.
EYU688 is being developed by Novartis AG, a multinational pharmaceutical company listed on the New York Stock Exchange under the ticker symbol NVS. The company is conducting clinical trials to evaluate the drug's potential as a treatment for dengue fever.
EYU688 is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not yet been approved by the FDA or other regulatory agencies. The ongoing Phase 2 trial is designed to evaluate the drug's efficacy, safety, and pharmacokinetics in patients with dengue fever.
EYU688 is being evaluated in a Phase 2 clinical trial with the identifier NCT06006559. This randomized, double-blind, placebo-controlled study is recruiting 108 participants aged 18 years and older with dengue fever. The trial is being conducted across multiple countries, including Brazil, Colombia, India, Malaysia, Mexico, Singapore, and Vietnam.
EYU688 is not FDA approved. It is an investigational drug currently in Phase 2 clinical trials for the treatment of dengue fever. The drug is being studied to determine its safety and efficacy, and it has not yet received marketing authorization from the FDA or any other regulatory body.
EYU688 is a small molecule being developed by Novartis for the treatment of dengue fever. The specific molecular target of EYU688 has not been disclosed in available information. The drug is currently being evaluated in a Phase 2 clinical trial to assess its efficacy, safety, and pharmacokinetics in patients with dengue.